1. Home
  2. REVB vs KALA Comparison

REVB vs KALA Comparison

Compare REVB & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.15

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.77

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REVB
KALA
Founded
2020
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
5.1M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
REVB
KALA
Price
$1.15
$0.77
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$31.50
AVG Volume (30 Days)
107.2K
21.0M
Earning Date
11-06-2025
11-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.83
$0.61
52 Week High
$60.48
$20.60

Technical Indicators

Market Signals
Indicator
REVB
KALA
Relative Strength Index (RSI) 63.48 38.68
Support Level $1.03 $0.71
Resistance Level $1.00 $0.86
Average True Range (ATR) 0.08 0.24
MACD 0.04 0.11
Stochastic Oscillator 93.03 12.87

Price Performance

Historical Comparison
REVB
KALA

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: